FindTrial
Sign In

Resistance and recurrence of colorectal cancer study

Understanding epigenetic memory driven therapy resistance and recurrence in colorectal cancer a patientbased and in vitro study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/03/064881
Enrollment
20
Registered
2024-03-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

Dr Nikhil Agarwal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Males or females age 20 years and above Patients undergoing surgery and or chemotherapy Patients whose treatment was performed in Max Institute of Cancer Care Saket

Exclusion criteria

Exclusion criteria: Avoid inclusion of human participants who have a combination of multiple other complications to eliminate the influence of those factors onto our data which should be purely based on our disease of interest

Design outcomes

Primary

MeasureTime frame
Understanding of expression of KDM6A and its down stream targets in the colorectal samples during surgery though RTPCR and or immune histochemistryTimepoint: 2 years—

Secondary

MeasureTime frame
Ability to demonstrate a correlation in expression status of the genes with recurrence after chemotherapyTimepoint: 2 years—

Countries

India

Contacts

Public ContactDr Poorvee Mathur

Max Super Speciality Hospital Saket New Delhi

nikhil@maxhealthcare.com9540946808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026